February 2020

Enfortumab Vedotin | Urothelial Carcinoma | Abstract 441

Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma

Enfortumab Vedotin | Urothelial Carcinoma | Abstract TPS591

Phase Ib/II umbrella trial to evaluate the safety and efficacy of multiple 2L cancer immunotherapy (CIT) combinations in advanced/metastatic urothelial carcinoma (mUC): MORPHEUS-mUC

HEOR | Urothelial Carcinoma | Abstract 458

Real-world outcomes in patients with locally advanced or metastatic urothelial carcinoma receiving taxane monotherapy following platinum and anti-PD-1/L1 therapy

Enfortumab Vedotin | Urothelial Carcinoma | Abstract TPS595

Study EV-103: New cohorts testing enfortumab vedotin alone or in combination with pembrolizumab in muscle invasive urothelial cancer